A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
|Videos|May 18, 2020
Evaluating Favipiravir For COVID 19
Author(s)Contagion® Editorial Staff
Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.
Advertisement
Segment Description: Armand Balboni, MD, PHD, CEO of Appili Therapeutics, discusses the firm's work with favipiravir on a new front for the drug — the global search for COVID-19 treatment and prevention therapies.
Dr. Armand Balboni, CEO of Appili Therapeutics has announced that his company is working with FUJIFILM Toyama Chemical on its favipiravir treatment, which is approved in Japan as an antiviral drug, on a new front for the drug — the global search for a pandemic treatment that can both prevent and treat COVID-19
Appili Therapeutics will sponsor the first clinical trial, phase 2, evaluating favipiravir for the prevention of COVID-19, as it has shown early efficacy against this disease. Appili is working with Canadian government agencies and infectious disease specialists to conduct the clinical trial at multiple long-term care facilities across Ontario.
Dr. Balboni worked with the drug when he was with the US department of defense and with the FDA during the pandemic flu and Ebola outbreaks. The treatment is administered orally, and not by injection, making it easier on patients.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
SubscribeAdvertisement
Related to this article
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
Advertisement
Advertisement